Skip to main content
. Author manuscript; available in PMC: 2020 Sep 2.
Published in final edited form as: Nat Cancer. 2020 Mar 9;1(3):329–344. doi: 10.1038/s43018-020-0037-3

Figure 7. Single cell transcriptomic analysis verifies lower CELSR2 and higher BCL2 in glucocorticoid-resistant primary ALL cells.

Figure 7.

(a.) Clustering of single cells (n= 2 patients) based upon the top 1000 most highly expressed genes. Both patients are independent of the discovery and validation cohorts; leukemia cells from one patient are sensitive (left) and one resistant to prednisolone (right). Clusters annotated to show CD19+ cells; red denotes control (untreated) and blue depicts cells after treatment with prednisolone 63μM for 96h (b.) CELSR2 expression from clustered single cell populations of sensitive and resistant patients either without treatment or after 96h prednisolone (c.) BCL2 expression from clustered single cell populations of sensitive and resistant patients (d.) Bar plot depicting greater proportion of sensitive leukemia cells (n=2,427 control cells; n= 924 treated cells) killed after treatment with prednisolone for 96h compared to resistant patient (n= 686 control cells; n=759 treated cells; two proportion z-test p-value; **** = p <0.0001). (e.) Violin plot representing kernel density of gene expression (individual points represent single cells) of CELSR2 or (f.) BCL2 in CD19+ leukemia cell populations comparing prednisolone treated to untreated cells in sensitive (n=2,427 control cells; n= 924 treated cells) or resistant patients (n= 686 control cells; n=759 treated cells; ** = p <0.01).